Knockout experiments using CRISPR/Cas9 in mouse melanoma models showed that the loss of IGF2BP2 led to increased expression of MHC class I molecules, increasing cells’ ability to promote intracellular IFN-γ expression in syngeneic T-lymphocytes. Here, IGF2BP2 is linked to melanoma.